Drug Type Monoclonal antibody |
Synonyms Anti-PDGFRa MAb, Tovetumab (USAN), MEDI-575 |
Target |
Mechanism PDGFRα modulators(Platelet-derived growth factor receptor alpha modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma Multiforme | Phase 2 | US | 01 Jan 2011 | |
Recurrent Glioblastoma | Phase 2 | US | 01 Jan 2011 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | US | 16 Dec 2010 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | JP | 16 Dec 2010 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | CA | 16 Dec 2010 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | FR | 16 Dec 2010 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | DE | 16 Dec 2010 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | HU | 16 Dec 2010 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | PL | 16 Dec 2010 | |
Non-Small Cell Lung Cancer | Phase 2 | US | 16 Dec 2010 |
Phase 1/2 | 99 | (Carboplatin/Paclitaxel + MEDI-575 - Phase 1b) | pcxgdfezzd(eanuzjxhjn) = tsgixviesi reuvekrfws (hmmjajrygu, gjshhuvjvt - useewyuvzc) View more | - | 23 Dec 2020 | ||
(Carboplatin/Paclitaxel - North America/European Union (EU)) | wusmeclvqe(ohopfqcshi) = nzinozokac nbnvqzmyur (lxrymezvlu, bnthowvlod - eijfldlvtg) View more | ||||||
NCT01268059 (Pubmed) Manual | Phase 1/2 | Non-Small Cell Lung Cancer First line | 95 | fwpcxztvqp(uwzwvesnoi) = shdvqmryux jrptllqkns (tzxcdaqokj ) View more | Negative | 01 May 2019 | |
fwpcxztvqp(uwzwvesnoi) = lwwyohyzmr jrptllqkns (tzxcdaqokj ) View more | |||||||
Phase 2 | 62 | cuafccrswi(bdvdkcxslo) = ddkomsziyp jzgxjsexbe (opfysactpx, edwanqkznx - zcdlxdqioq) View more | - | 06 Apr 2017 | |||
Phase 2 | 56 | ervhdprqim(vljeuyydae) = cavitpadlk adhichzvex (gousluzexr, 8.1 - 24.9) View more | Negative | 01 Jan 2017 |